Atara Biotherapeutics Earlier Reported Q3 EPS $(1.31) Beats $(1.44) Estimate

Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly losses of $(1.31) per share which beat the analyst consensus estimate of $(1.44) by 9.03 percent. This is a 1.55 percent decrease over losses of $(1.29) per share

Benzinga · 11/07/2019 14:35

Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly losses of $(1.31) per share which beat the analyst consensus estimate of $(1.44) by 9.03 percent. This is a 1.55 percent decrease over losses of $(1.29) per share from the same period last year.